BioPlus Co Ltd
KOSDAQ:099430
BioPlus Co Ltd
Total Equity
BioPlus Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Total Equity
₩133.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Total Equity
₩480.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
SD Biosensor Inc
KRX:137310
|
Total Equity
₩2.9T
|
CAGR 3-Years
10%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Total Equity
₩377.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
19%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Total Equity
₩171.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Total Equity
₩154.9B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Total Equity?
Total Equity
133.5B
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Total Equity amounts to 133.5B KRW.
What is BioPlus Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
50%
Over the last year, the Total Equity growth was 4%. The average annual Total Equity growth rates for BioPlus Co Ltd have been 19% over the past three years , 50% over the past five years .
